Literature DB >> 22458883

Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007.

N De Castro1, E Mazoyer, R Porcher, E Raffoux, F Suarez, P Ribaud, O Lortholary, J-M Molina.   

Abstract

We report a retrospective study of 24 patients with haematological malignancy and hepatosplenic candidiasis. Clinical and biological features were similar to previous reports. No patient previously received antifungal prophylaxis. Liver or spleen histological examination revealed yeasts in 6/24 patients (25%) on direct examination but all cultures were negative. After a median duration of 7 months, antifungal treatment was discontinued in 58% of the patients with no relapse. Eleven (46%) patients died during follow up. After multivariate analysis, independent factors associated with death were the duration of neutropenia (p 0.022) and relapsing haematological malignancy (p 0.015).
© 2012 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22458883     DOI: 10.1111/j.1469-0691.2012.03819.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

2.  Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?

Authors:  Joffrey van Prehn; C Willemien Menke-van der Houven van Oordt; Madelon L de Rooij; Ellen Meijer; Marije K Bomers; Karin van Dijk
Journal:  Oncologist       Date:  2017-05-03

3.  Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study.

Authors:  Inès Boussen; Quentin Lisan; Emmanuel Raffoux; Roberta Di Blasi; Nicolas Boissel; Eric Oksenhendler; Lionel Adès; Aliénor Xhaard; Stéphane Bretagne; Alexandre Alanio; Jean-Michel Molina; Blandine Denis
Journal:  Open Forum Infect Dis       Date:  2022-03-07       Impact factor: 3.835

4.  Clinical feature, image findings and outcome of hepatosplenic candidiasis in patients with acute myeloid leukemia.

Authors:  Hung Chang; Ming-Chung Kuo; Tzung-Chih Tang; Tung-Liang Lin; Jin-Hou Wu
Journal:  Biomed J       Date:  2020-11-18       Impact factor: 7.892

5.  Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.

Authors:  Roberta Della Pepa; M Picardi; F Sorà; M Stamouli; A Busca; A Candoni; M Delia; R Fanci; V Perriello; M Zancanella; A Nosari; P Salutari; F Marchesi; F Pane; L Pagano
Journal:  Support Care Cancer       Date:  2016-04-14       Impact factor: 3.603

Review 6.  Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies.

Authors:  Marco Fiore; Marco Cascella; Sabrina Bimonte; Alberto Enrico Maraolo; Ivan Gentile; Vincenzo Schiavone; Maria Caterina Pace
Journal:  Infect Drug Resist       Date:  2018-01-29       Impact factor: 4.003

Review 7.  Candida-Related Immune Response Inflammatory Syndrome Treated with Adjuvant Corticosteroids and Review of the Pediatric Literature.

Authors:  Dildar Bahar Genç; Sema Vural; Nafiye Urgancı; Tuğçe Kurtaraner; Nazan Dalgıç
Journal:  Turk J Haematol       Date:  2016-10-18       Impact factor: 1.831

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.